Related Experiment Video
Updated: Jun 13, 2026
10:39
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
Regulatory CD4+ T cells in allergic asthma.
Vincent A Carlier1, Luc P Vanderelst, Marc G Jacquemin
1University of Leuven, Center for Molecular and Vascular Biology, Campus Gasthuisberg, O&N, Herestraat 49, 3000 Leuven, Belgium. vincent.carlier@med.kuleuven.be
Expert Review of Clinical Immunology
|May 19, 2010
Summary
Regulatory T cells (Tregs) suppress immune responses. New research suggests cytotoxic Tregs release granzymes to induce apoptosis, offering a potential treatment for allergic asthma via targeted vaccination strategies.
Area of Science:
- Immunology
- Cellular Biology
Background:
- Regulatory T cells (Tregs) are crucial for downregulating immune responses to foreign antigens.
- The precise mechanisms of Treg-mediated suppression are not fully understood.
- Natural Tregs may exert suppressive effects through cytotoxic mechanisms involving granzyme release.
Purpose of the Study:
- To investigate the role of cytotoxicity in Treg function.
- To explore the potential of inducing antigen-specific cytotoxic Tregs for therapeutic purposes.
- To evaluate a novel vaccination strategy for allergic asthma treatment.
Main Methods:
- Discussion of existing data on Treg cytotoxicity and granzyme-mediated apoptosis.
- Optimization of a vaccination strategy to elicit cytotoxic Tregs.
- Focus on targeting allergens involved in allergic asthma.
Main Results:
- Natural Tregs may possess cytotoxic capacity, inducing apoptosis in effector T cells and antigen-presenting cells.
- A vaccination strategy was successfully optimized to generate cytotoxic antigen-specific Tregs.
- This approach targets allergens relevant to allergic asthma.
Conclusions:
- Cytotoxicity, via granzyme release, is a potential mechanism for Treg-mediated suppression.
- The developed vaccination strategy shows promise for inducing therapeutic Tregs.
- This approach may offer a novel treatment avenue for allergic asthma.
Related Concept Videos
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...